In the course of reinventing, refocusing, and reinvigorating the company, Strongbridge Biopharma has reached a series of pivotal business and clinical milestones.
In December 2016, Strongbridge Biopharma acquired the US rights to KEVEYIS® (dichlorphenamide). This acquisition is part of our commitment to expand our portfolio and help meet the needs of patients with rare and orphan diseases that are underdiagnosed and undertreated.
Recent clinical milestones reflect our focus on rare diseases and our organizational agility in meeting the challenges of drug development.
For KEVEYIS important safety information, please see full Prescribing Information (PDF).